Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New stem cell trick may help kids fight tough cancers

NCT ID NCT01625351

First seen Feb 06, 2026 · Last updated Jun 23, 2026 · Updated 20 times

Summary

This early-phase study tested a new way to do stem cell transplants in 23 children whose solid tumors or lymphomas had come back. The method uses a special filter to remove certain immune cells from the donor's stem cells, aiming to help the child's body recover faster. The main goal was to see if the transplant was even possible, with researchers also tracking survival and infection rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

stem cell transplant with immune-suppressing drugs (alemtuzumab, fludarabine, sirolimus)

What this could lead to

If successful, this approach could make stem cell transplants safer and more effective for children with hard-to-treat cancers, potentially improving survival.

What could go wrong

This is a very early (phase I) and small study (23 children). The main goal is just to see if the transplant is feasible, not to prove it works. There are serious risks like infection and graft failure.

Conditions

The condition(s) this trial relates to.

clear cell adenocarcinoma digestive system neoplasm Digestive System Neoplasms Ewing sarcoma germ cell tumor hepatocellular carcinoma lymphoma melanoma Neoplasms, Germ Cell and Embryonal neuroblastoma renal cell carcinoma rhabdoid tumor rhabdomyosarcoma Wilms tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.